<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01699113</url>
  </required_header>
  <id_info>
    <org_study_id>05-021</org_study_id>
    <nct_id>NCT01699113</nct_id>
  </id_info>
  <brief_title>Effects of YF476 and Rabeprazole on Gastric Function</brief_title>
  <official_title>Effects of YF476, a Gastrin Antagonist, and Rabeprazole, a Proton Pump Inhibitor, Alone and in Combination, on Gastric Function in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trio Medicines Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trio Medicines Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are to find out in healthy subjects if:&#xD;
&#xD;
        -  YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a&#xD;
           proton pump inhibitor;&#xD;
&#xD;
        -  YF476 also prevents rebound hyperacidity after stopping rabeprazole; and&#xD;
&#xD;
        -  YF476 by itself causes neither ECL-cell hyperplasia after repeated doses nor rebound&#xD;
           hyperacidity after stopping YF476.&#xD;
&#xD;
      The secondary objectives are to:&#xD;
&#xD;
        -  assess the safety and tolerability of YF476, alone and in combination with rabeprazole;&#xD;
&#xD;
        -  compare the effects of YF476, alone and in combination with rabeprazole, on serum&#xD;
           gastrin and plasma CgA and SST;&#xD;
&#xD;
        -  assess if there is a pharmacokinetic interaction between YF476 and rabeprazole;&#xD;
&#xD;
        -  assess the pharmacokinetics of repeat doses of YF476 by itself; and&#xD;
&#xD;
        -  study the metabolism of YF476.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We want to know if YF476 prevents ECL-cell hyperplasia induced by PPI, and rebound&#xD;
      hyperacidity after PPI withdrawal, in man, as it does in the rat. A positive result would&#xD;
      support further studies to assess if a combination of YF476 and a PPI is a better way of&#xD;
      treating patients with peptic ulcer disease and GORD than a PPI alone. Equally, we want to&#xD;
      know if YF476 by itself not only inhibits gastric acid secretion but also does not cause&#xD;
      ECL-cell hyperplasia and rebound hyperacidity after withdrawal. A positive result would&#xD;
      support further studies to assess if YF476 alone is an alternative and perhaps better&#xD;
      treatment for patients with peptic ulcer disease and GORD than a PPI alone. The study design&#xD;
      is important. We need to ask ourselves several questions.&#xD;
&#xD;
      First, which PPI should we use? Omeprazole has been studied more than other PPI, and is&#xD;
      probably still the most widely used PPI in the clinic. A disadvantage of omeprazole is that&#xD;
      its metabolism is affected by genetic polymorphism. Studies of human liver microsomes in&#xD;
      vitro (Yamazaki et al 1997) show that omeprazole is metabolised by 5-hydroxylation (catalysed&#xD;
      by CYP2C19, and to a lesser extent CYP3A4) and sulphoxidation (catalysed by CYP3A4). YF476&#xD;
      inhibits CYP3A4/5 in vitro; but we don't know how relevant that is in vivo. CYP2C19 has 3&#xD;
      genotypes: homozygous extensive metabolisers, with higher enzymatic activity; heterozygous&#xD;
      extensive metabolisers, with moderate enzymatic activity; and poor metabolisers, with&#xD;
      markedly impaired enzymatic activity. Consequently, in CYP2C19 homozygous extensive&#xD;
      metabolisers, acid suppression by omeprazole is reduced compared with heterozygous and poor&#xD;
      metabolisers (Shirai et al 2001). Homozygous extensive metabolisers comprise about 70% of the&#xD;
      European and USA populations and about 30% of the Asian population. Recently, a new CYP2C19&#xD;
      gene variant that causes ultrarapid metabolism of omeprazole has been identified in 18% of&#xD;
      Swedes (Sim et al 2006). So, if we use omeprazole, we should genotype subjects for CYP2C19.&#xD;
      Ideally, we should stratify their allocation to treatments, to try to avoid confounding the&#xD;
      results. But, we are unlikely to be able to get the genotyping results quickly enough after&#xD;
      screening to make stratification practical.&#xD;
&#xD;
      Rabeprazole, unlike omeprazole, is metabolised mainly via a non-enzymatic pathway with minor&#xD;
      CYP2C19 and CYP3A4 involvement. Therefore, acid suppression by rabeprazole is less affected&#xD;
      by CYP2C19 genotype (Shirai et al 2001; Miura et al 2006), which is one reason for using&#xD;
      rabeprazole instead of omeprazole. Omeprazole and rabeprazole are both off-patent, so a&#xD;
      combination product of YF476 and either PPI is possible.&#xD;
&#xD;
      Second, what dose of PPI should we use, and for how long? The dose of PPI should be one that&#xD;
      is clinically relevant. If the choice of PPI is omeprazole, the dose should be 40 mg daily,&#xD;
      because 20 mg -- the standard clinical dose -- was less effective than the recommended doses&#xD;
      of other PPI in raising gastric pH (Warrington et al 2006). Rabeprazole 20 mg was more&#xD;
      effective than esomeprazole 20 mg in those studies, another reason for using rabeprazole&#xD;
      (Warrington et al 2005). Taking everything into account, we have decided to use rabeprazole&#xD;
      20 mg daily for our study.&#xD;
&#xD;
      The duration of PPI dosing is probably more important than the choice of PPI and dose. The&#xD;
      longer the duration of dosing, the more likely we are to show the morphological changes of&#xD;
      ECL-cell hyperplasia. But ethical considerations and compliance issues mean that we have to&#xD;
      compromise over duration of dosing. The available evidence suggests that 2 weeks is not long&#xD;
      enough to induce ECL-cell hyperplasia, whereas 8-12 weeks may be more than long enough. So, 6&#xD;
      weeks seems a reasonable compromise.&#xD;
&#xD;
      Third, how long after stopping the PPI should we assess rebound hyperacidity? Early studies&#xD;
      in man failed to show rebound hyperacidity after stopping omeprazole because the assessments&#xD;
      were done too soon (Prewett et al 1991). PPIs are non-competitive inhibitors of the proton&#xD;
      pump, which takes days to regenerate fully. The available evidence suggests that 2 weeks&#xD;
      after PPI withdrawal is long enough to study rebound hyperacidity.&#xD;
&#xD;
      Fourth, what dose of YF476 should we use? Single and repeated doses of 100 mg daily were well&#xD;
      tolerated and completely suppressed pentagastrin-stimulated increases in gastric acid volume&#xD;
      and H+ content in healthy subjects. The toxicology and toxicokinetic studies support dosing&#xD;
      of 100 mg daily for up to 13 weeks. So, a dosing schedule of 100 mg daily for 6 weeks is&#xD;
      appropriate.&#xD;
&#xD;
      Fifth, is it safe to give a PPI and YF476 together? No safety problems were reported when&#xD;
      rats were given omeprazole and YM022, an enantiomer of YF476, for 13 weeks (Nishida et al&#xD;
      1995). Also, no safety problems were reported when omeprazole and YF476 were given to rats&#xD;
      for 8 weeks (Chen et al 2000). However, whatever PPI we use, we should assay blood&#xD;
      concentrations of PPI and YF476 (Redrup et al 2002) at the start and end of dosing, lest a&#xD;
      drug-drug interaction confound the results of the outcome measures.&#xD;
&#xD;
      Sixth, what tests of gastric function and ECL cells should we use to compare the treatments?&#xD;
      We should study: plasma gastrin, to assess the degree of hypergastrinaemia; plasma CgA, a&#xD;
      marker of ECL-cell hyperplasia; plasma SST, a marker of D-cell activity;&#xD;
      pentagastrin-stimulated increases in gastric acid volume and H+ content, and 24-hour&#xD;
      ambulatory pH, to compare anti-secretory responses during and after stopping treatments;&#xD;
      gastric biopsies, to assess changes in ECL-cell histology and enzymes; and dyspepsia&#xD;
      symptoms, to assess occurrence of symptomatic rebound hyperacidity after stopping treatment.&#xD;
&#xD;
      Seventh, should the study be crossover or parallel-group in design? In healthy subjects, a&#xD;
      crossover study is often the ideal design. Comparisons are made within rather than between&#xD;
      subjects, which reduces the variability of the results. But, a crossover design is not&#xD;
      practical given the long dosage period and the demanding procedures. By using rabeprazole, we&#xD;
      avoid the potential problem of between-subject differences attributable to CYP2C19 genetic&#xD;
      polymorphism. So, a parallel-group design with 3 groups of subjects randomised to either&#xD;
      YF476, rabeprazole, or a combination of YF476 and rabeprazole, is a sensible solution.&#xD;
&#xD;
      Eighth, should we have identical treatments and a placebo group? We can over-encapsulate the&#xD;
      treatments to make them identical so that the study is double blind in design. Ideally, we&#xD;
      should have a placebo group, but if the study is double blind in design and the methods are&#xD;
      mostly objective, a placebo group is not essential.&#xD;
&#xD;
      Finally, should we use patients or healthy subjects? Healthy subjects and patients with&#xD;
      peptic ulcer disease or GORD all develop hypergastrinaemia and ECL-cell hyperplasia after&#xD;
      repeated dosing with a PPI, and rebound hyperacidity after stopping the PPI. Nevertheless,&#xD;
      the study is best done in healthy subjects because they are more likely to comply with the&#xD;
      demanding study procedures, more homogeneous, more robust, and not on medication. The YF476&#xD;
      reproductive toxicology studies justify including women who are not at risk of pregnancy.&#xD;
      However, H pylori-positive subjects should be excluded. In a recent UK community study, 15%&#xD;
      of people were H pylori-positive (Lane et al 2006).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of pentagastrin-stimulated gastric volume</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of pentagastrin-stimulated H+ content (titratable acidity)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of pentagastrin-stimulated pH</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of pentagastrin-stimulated bicarbonate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Histology of ECL cells</measure>
    <description>4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.&#xD;
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunostaining of HDC and CgA</measure>
    <description>4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.&#xD;
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electron microscopy of gastric mucosal biopsies</measure>
    <description>4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.&#xD;
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of 24-h intragastric pH</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of 24-h serum gastrin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of 24-h plasma SST and CgA</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of dyspepsia symptoms; antacid usage</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetics of YF476 in blood and urine</measure>
    <description>Blood samples for assay of YF476 and/or rabeprazole: before and frequently up to 24 h after the first dose, and at the end of treatment (Day 40); and before dosing on clinic visits during the treatment period, to assess compliance. 3 additional blood samples (4 mL) on Day 40 for future analysis of metabolites. Urine collection 0-24 h after the first dose and at the end of treatment (Day 40), for future analysis of metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of pharmacokinetics of rabeprazole in blood and urine</measure>
    <description>Blood samples for assay of YF476 and/or rabeprazole: before and frequently up to 24 h after the first dose, and at the end of treatment (Day 40); and before dosing on clinic visits during the treatment period, to assess compliance. 3 additional blood samples (4 mL) on Day 40 for future analysis of metabolites. Urine collection 0-24 h after the first dose and at the end of treatment (Day 40), for future analysis of metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of safety assessments</measure>
    <description>Physical examination; vital signs; ECG (especially QTc interval); safety tests of blood and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypergastrinaemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YF476</intervention_name>
    <description>Subjects will be randomised to once daily treatment by mouth for 6 weeks with:&#xD;
YF476 100 mg; or&#xD;
rabeprazole 20 mg; or&#xD;
a combination of YF476 100 mg and rabeprazole 20 mg.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Subjects will be randomised to once daily treatment by mouth for 6 weeks with:&#xD;
YF476 100 mg; or&#xD;
rabeprazole 20 mg; or&#xD;
a combination of YF476 100 mg and rabeprazole 20 mg.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, deemed healthy on the basis of a clinical history, physical examination,&#xD;
             ECG and safety tests of blood and urine;&#xD;
&#xD;
          -  able to give fully-informed, written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, lactating or using a steroid contraceptive.&#xD;
&#xD;
          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at&#xD;
             the pre-trial screening assessment that could interfere with the objectives of the&#xD;
             trial or the safety of the subject.&#xD;
&#xD;
          -  Presence of acute or chronic illness or history of chronic illness sufficient to&#xD;
             invalidate the subject's participation in the trial or make it unnecessarily&#xD;
             hazardous.&#xD;
&#xD;
          -  Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes&#xD;
             mellitus, coronary heart disease, or history of any psychotic mental illness.&#xD;
&#xD;
          -  Evidence of high serum gastrin at screening or achlorhydria at baseline.&#xD;
&#xD;
          -  Presence or history of severe adverse reaction to any drug.&#xD;
&#xD;
          -  Use of a prescription medicine or antacids during the 28 days before the trial or use&#xD;
             of an over-the-counter medication, with the exception of paracetamol, during the 7&#xD;
             days before the trial.&#xD;
&#xD;
          -  Participation in a trial of a new drug substance or a prescription medicine within the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  Presence or history of drug or alcohol abuse, or intake of more than 28 units of&#xD;
             alcohol weekly (for men) or 21 units of alcohol weekly (for women).&#xD;
&#xD;
          -  Blood pressure and heart rate in supine position at the screening examination outside&#xD;
             the ranges 90-160 mm Hg systolic, 40-95 mm Hg diastolic; heart rate 40_100 beats/min.&#xD;
&#xD;
          -  Possibility of the subject not co-operating with requirements of the protocol.&#xD;
&#xD;
          -  Evidence of drug abuse on urine testing.&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C, HIV1 or HIV2.&#xD;
&#xD;
          -  Loss of &gt; 400 mL blood, e.g. blood donation, in the 3 months before the trial.&#xD;
&#xD;
          -  Objection by the General Practitioner (GP) to the subject entering the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Boyce</last_name>
    <role>Study Director</role>
    <affiliation>Trio Medicines Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YF476</keyword>
  <keyword>gastrin receptor antagonist</keyword>
  <keyword>gastric pH</keyword>
  <keyword>gastrin</keyword>
  <keyword>rabeprazole</keyword>
  <keyword>proton-pump inhibitor</keyword>
  <keyword>gastric function</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01699113
org study id: 05-021
nct id: NCT01699113
lead sponsor: 
has dmc: No
The primary objectives are to find out in healthy subjects if:

        -  YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a
           proton pump inhibitor;

        -  YF476 also prevents rebound hyperacidity after stopping rabeprazole; and

        -  YF476 by itself causes neither ECL-cell hyperplasia after repeated doses nor rebound
           hyperacidity after stopping YF476.

      The secondary objectives are to:

        -  assess the safety and tolerability of YF476, alone and in combination with rabeprazole;

        -  compare the effects of YF476, alone and in combination with rabeprazole, on serum
           gastrin and plasma CgA and SST;

        -  assess if there is a pharmacokinetic interaction between YF476 and rabeprazole;

        -  assess the pharmacokinetics of repeat doses of YF476 by itself; and

        -  study the metabolism of YF476.
We want to know if YF476 prevents ECL-cell hyperplasia induced by PPI, and rebound
      hyperacidity after PPI withdrawal, in man, as it does in the rat. A positive result would
      support further studies to assess if a combination of YF476 and a PPI is a better way of
      treating patients with peptic ulcer disease and GORD than a PPI alone. Equally, we want to
      know if YF476 by itself not only inhibits gastric acid secretion but also does not cause
      ECL-cell hyperplasia and rebound hyperacidity after withdrawal. A positive result would
      support further studies to assess if YF476 alone is an alternative and perhaps better
      treatment for patients with peptic ulcer disease and GORD than a PPI alone. The study design
      is important. We need to ask ourselves several questions.

      First, which PPI should we use? Omeprazole has been studied more than other PPI, and is
      probably still the most widely used PPI in the clinic. A disadvantage of omeprazole is that
      its metabolism is affected by genetic polymorphism. Studies of human liver microsomes in
      vitro (Yamazaki et al 1997) show that omeprazole is metabolised by 5-hydroxylation (catalysed
      by CYP2C19, and to a lesser extent CYP3A4) and sulphoxidation (catalysed by CYP3A4). YF476
      inhibits CYP3A4/5 in vitro; but we don't know how relevant that is in vivo. CYP2C19 has 3
      genotypes: homozygous extensive metabolisers, with higher enzymatic activity; heterozygous
      extensive metabolisers, with moderate enzymatic activity; and poor metabolisers, with
      markedly impaired enzymatic activity. Consequently, in CYP2C19 homozygous extensive
      metabolisers, acid suppression by omeprazole is reduced compared with heterozygous and poor
      metabolisers (Shirai et al 2001). Homozygous extensive metabolisers comprise about 70% of the
      European and USA populations and about 30% of the Asian population. Recently, a new CYP2C19
      gene variant that causes ultrarapid metabolism of omeprazole has been identified in 18% of
      Swedes (Sim et al 2006). So, if we use omeprazole, we should genotype subjects for CYP2C19.
      Ideally, we should stratify their allocation to treatments, to try to avoid confounding the
      results. But, we are unlikely to be able to get the genotyping results quickly enough after
      screening to make stratification practical.

      Rabeprazole, unlike omeprazole, is metabolised mainly via a non-enzymatic pathway with minor
      CYP2C19 and CYP3A4 involvement. Therefore, acid suppression by rabeprazole is less affected
      by CYP2C19 genotype (Shirai et al 2001; Miura et al 2006), which is one reason for using
      rabeprazole instead of omeprazole. Omeprazole and rabeprazole are both off-patent, so a
      combination product of YF476 and either PPI is possible.

      Second, what dose of PPI should we use, and for how long? The dose of PPI should be one that
      is clinically relevant. If the choice of PPI is omeprazole, the dose should be 40 mg daily,
      because 20 mg -- the standard clinical dose -- was less effective than the recommended doses
      of other PPI in raising gastric pH (Warrington et al 2006). Rabeprazole 20 mg was more
      effective than esomeprazole 20 mg in those studies, another reason for using rabeprazole
      (Warrington et al 2005). Taking everything into account, we have decided to use rabeprazole
      20 mg daily for our study.

      The duration of PPI dosing is probably more important than the choice of PPI and dose. The
      longer the duration of dosing, the more likely we are to show the morphological changes of
      ECL-cell hyperplasia. But ethical considerations and compliance issues mean that we have to
      compromise over duration of dosing. The available evidence suggests that 2 weeks is not long
      enough to induce ECL-cell hyperplasia, whereas 8-12 weeks may be more than long enough. So, 6
      weeks seems a reasonable compromise.

      Third, how long after stopping the PPI should we assess rebound hyperacidity? Early studies
      in man failed to show rebound hyperacidity after stopping omeprazole because the assessments
      were done too soon (Prewett et al 1991). PPIs are non-competitive inhibitors of the proton
      pump, which takes days to regenerate fully. The available evidence suggests that 2 weeks
      after PPI withdrawal is long enough to study rebound hyperacidity.

      Fourth, what dose of YF476 should we use? Single and repeated doses of 100 mg daily were well
      tolerated and completely suppressed pentagastrin-stimulated increases in gastric acid volume
      and H+ content in healthy subjects. The toxicology and toxicokinetic studies support dosing
      of 100 mg daily for up to 13 weeks. So, a dosing schedule of 100 mg daily for 6 weeks is
      appropriate.

      Fifth, is it safe to give a PPI and YF476 together? No safety problems were reported when
      rats were given omeprazole and YM022, an enantiomer of YF476, for 13 weeks (Nishida et al
      1995). Also, no safety problems were reported when omeprazole and YF476 were given to rats
      for 8 weeks (Chen et al 2000). However, whatever PPI we use, we should assay blood
      concentrations of PPI and YF476 (Redrup et al 2002) at the start and end of dosing, lest a
      drug-drug interaction confound the results of the outcome measures.

      Sixth, what tests of gastric function and ECL cells should we use to compare the treatments?
      We should study: plasma gastrin, to assess the degree of hypergastrinaemia; plasma CgA, a
      marker of ECL-cell hyperplasia; plasma SST, a marker of D-cell activity;
      pentagastrin-stimulated increases in gastric acid volume and H+ content, and 24-hour
      ambulatory pH, to compare anti-secretory responses during and after stopping treatments;
      gastric biopsies, to assess changes in ECL-cell histology and enzymes; and dyspepsia
      symptoms, to assess occurrence of symptomatic rebound hyperacidity after stopping treatment.

      Seventh, should the study be crossover or parallel-group in design? In healthy subjects, a
      crossover study is often the ideal design. Comparisons are made within rather than between
      subjects, which reduces the variability of the results. But, a crossover design is not
      practical given the long dosage period and the demanding procedures. By using rabeprazole, we
      avoid the potential problem of between-subject differences attributable to CYP2C19 genetic
      polymorphism. So, a parallel-group design with 3 groups of subjects randomised to either
      YF476, rabeprazole, or a combination of YF476 and rabeprazole, is a sensible solution.

      Eighth, should we have identical treatments and a placebo group? We can over-encapsulate the
      treatments to make them identical so that the study is double blind in design. Ideally, we
      should have a placebo group, but if the study is double blind in design and the methods are
      mostly objective, a placebo group is not essential.

      Finally, should we use patients or healthy subjects? Healthy subjects and patients with
      peptic ulcer disease or GORD all develop hypergastrinaemia and ECL-cell hyperplasia after
      repeated dosing with a PPI, and rebound hyperacidity after stopping the PPI. Nevertheless,
      the study is best done in healthy subjects because they are more likely to comply with the
      demanding study procedures, more homogeneous, more robust, and not on medication. The YF476
      reproductive toxicology studies justify including women who are not at risk of pregnancy.
      However, H pylori-positive subjects should be excluded. In a recent UK community study, 15%
      of people were H pylori-positive (Lane et al 2006).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: Double (Participant, Investigator)
measure: Measurement of pentagastrin-stimulated gastric volume
measure: Measurement of pentagastrin-stimulated H+ content (titratable acidity)
measure: Measurement of pentagastrin-stimulated pH
measure: Measurement of pentagastrin-stimulated bicarbonate
measure: Histology of ECL cells
description: 4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.
measure: Immunostaining of HDC and CgA
description: 4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.
measure: Electron microscopy of gastric mucosal biopsies
description: 4 biopsy specimens were taken from the oxyntic mucosa of the body of the stomach. The specimens were prepared and coded for blinded analysis.
The biopsy specimens were analysed by histology, immunohistochemistry of HDC and CgA, and electron microscopy.
measure: Measurement of 24-h intragastric pH
measure: Measurement of 24-h serum gastrin
measure: Measurement of 24-h plasma SST and CgA
measure: Measurement of dyspepsia symptoms; antacid usage
measure: Measurement of pharmacokinetics of YF476 in blood and urine
description: Blood samples for assay of YF476 and/or rabeprazole: before and frequently up to 24 h after the first dose, and at the end of treatment (Day 40); and before dosing on clinic visits during the treatment period, to assess compliance. 3 additional blood samples (4 mL) on Day 40 for future analysis of metabolites. Urine collection 0-24 h after the first dose and at the end of treatment (Day 40), for future analysis of metabolites.
measure: Measurement of pharmacokinetics of rabeprazole in blood and urine
description: Blood samples for assay of YF476 and/or rabeprazole: before and frequently up to 24 h after the first dose, and at the end of treatment (Day 40); and before dosing on clinic visits during the treatment period, to assess compliance. 3 additional blood samples (4 mL) on Day 40 for future analysis of metabolites. Urine collection 0-24 h after the first dose and at the end of treatment (Day 40), for future analysis of metabolites.
measure: Measurement of safety assessments
description: Physical examination; vital signs; ECG (especially QTc interval); safety tests of blood and urine
measure: Number of adverse events
intervention type: Drug
intervention name: YF476
description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg.
intervention type: Drug
intervention name: Rabeprazole
description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg.
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Malcolm Boyce
role: Study Director
affiliation: Trio Medicines Limited
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Rabeprazole